MV Chandrakanth· @ChandrakanthMv · X·· 1 天前评分70
正文 · 原文
MARIPOSA-2 vs SAFFRON | #ESMO2026
Two phase III trials. Two strategies after osimertinib progression in EGFR-mutant NSCLC.
🔹 MARIPOSA-2: Amivantamab + chemotherapy, without MET selection. PFS HR 0.48; OS HR 0.73 (not significant at IA2).
🟠 SAFFRON: Chemotherapy-free osimertinib + savolitinib in MET-high disease. PFS HR 0.55; OS HR 0.68 (p=0.010).
Broad applicability vs biomarker-selected precision.
⚠️ Cross-trial comparisons cannot establish superiority.
Refs: Passaro et al., Ann Oncol 2024; Popat et al., ESMO 2024; Lu et al., ESMO 2026 (LBA6).
@myESMO @OncoAlert @larvol #MVOnco #LungCancer
52 浏览 · 2 赞 · 0 转发 · 0 回复
来源：MV Chandrakanth · x.com